Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

28 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The acute and late toxicity results of a randomized phase II dose-escalation trial in non-small cell lung cancer (PET-boost trial).
van Diessen J, De Ruysscher D, Sonke JJ, Damen E, Sikorska K, Reymen B, van Elmpt W, Westman G, Fredberg Persson G, Dieleman E, Bjorkestrand H, Faivre-Finn C, Belderbos J. van Diessen J, et al. Among authors: van elmpt w. Radiother Oncol. 2019 Feb;131:166-173. doi: 10.1016/j.radonc.2018.09.019. Epub 2018 Oct 13. Radiother Oncol. 2019. PMID: 30327236 Clinical Trial.
Radiotherapy dose and fractionation for stage III NSCLC.
Belderbos J, Walraven I, van Diessen J, Verheij M, de Ruysscher D. Belderbos J, et al. Among authors: van diessen j. Lancet Oncol. 2015 Apr;16(4):e156-7. doi: 10.1016/S1470-2045(15)70121-X. Lancet Oncol. 2015. PMID: 25846093 No abstract available.
Long-term follow-up of patients with locally advanced non-small cell lung cancer receiving concurrent hypofractionated chemoradiotherapy with or without cetuximab.
Walraven I, van den Heuvel M, van Diessen J, Schaake E, Uyterlinde W, Aerts J, Koppe F, Codrington H, Kunst P, Dieleman E, van de Vaart P, Verheij M, Belderbos J. Walraven I, et al. Among authors: van diessen j, van de vaart p, van den heuvel m. Radiother Oncol. 2016 Mar;118(3):442-6. doi: 10.1016/j.radonc.2016.02.011. Epub 2016 Feb 15. Radiother Oncol. 2016. PMID: 26900091 Clinical Trial.
A secondary analysis of FDG spatio-temporal consistency in the randomized phase II PET-boost trial in stage II-III NSCLC.
La Fontaine M, Vogel W, van Diessen J, van Elmpt W, Reymen B, Persson G, Westman G, De Ruysscher D, Belderbos J, Sonke JJ. La Fontaine M, et al. Among authors: van diessen j, van elmpt w. Radiother Oncol. 2018 May;127(2):259-266. doi: 10.1016/j.radonc.2018.03.020. Epub 2018 Apr 27. Radiother Oncol. 2018. PMID: 29709378 Clinical Trial.
In response to Park, et al.
van Diessen JNA, Kwint MH, Sonke JJ, Belderbos JSA. van Diessen JNA, et al. Radiother Oncol. 2020 Jun;147:245-246. doi: 10.1016/j.radonc.2020.03.036. Epub 2020 Apr 4. Radiother Oncol. 2020. PMID: 32312603 No abstract available.
28 results